Author
@BioStocks BioStocks
grade Cx.com/BioStocks ↗
High-volume biotech catalyst news desk relaying FDA, trial, and pharma M&A flow
Aggregates and relays real-time biotech/pharma catalysts — F
trader score
-1.77
hit rate
35%
mean α
-2.04%
signals 14d
63
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 20 scored bets: 35% hit rate, -2.04% mean alpha, trader score -1.77. Their last-14d mentions, direction-adjusted, have moved -6.5% since posting (mean over 30 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-10-15 | QURE | @BioStocks | +0.40 | UBS assumed coverage of QURE with a Buy rating and $48 price target. | -0.4% | tweet ↗ |
| 2026-10-15 | TARA | @BioStocks | +0.25 | TARA completed enrollment in a Phase 2b trial segment, with interim data expected in Q4 2026. | · | tweet ↗ |
| 2026-10-15 | TRAX | @BioStocks | -0.15 | TRAX announced a $200 million PIPE priced at $32.75 per share. | · | tweet ↗ |
| 2026-10-15 | ANL | @BioStocks | +0.40 | ANL entered a clinical collaboration with Lilly and Merck KGaA to test AN4035 plus cetuximab. | — | tweet ↗ |
| 2026-10-15 | LLY | @BioStocks | +0.10 | ANL entered a clinical collaboration with Lilly and Merck KGaA to test AN4035 plus cetuximab. | +1.7% | tweet ↗ |
| 2026-10-15 | CLRB | @BioStocks | +0.50 | CLRB presented compelling Phase 2b efficacy data for iopofosine I-131. | · | tweet ↗ |
| 2026-10-15 | AQST | @BioStocks | +0.50 | The FDA accepted AQST's Anaphylm NDA resubmission and set a March 16, 2027 PDUFA date. | -1.5% | tweet ↗ |
| 2026-10-15 | PRAX | @BioStocks | +0.40 | UBS initiated PRAX with a Buy rating and $706 target. | +1.9% | tweet ↗ |
| 2026-10-15 | PYPL | @BioStocks | -0.40 | BofA downgraded PayPal to Underperform with a $53 price target. | -0.2% | tweet ↗ |
| 2026-10-15 | ARWR | @BioStocks | +0.40 | UBS assumed coverage of ARWR with a Buy rating and $109 target. | -0.8% | tweet ↗ |
| 2026-10-14 | VIR | @BioStocks | +0.50 | Reports a VIR-GILD oncology collaboration with $90 million upfront and a premium equity investment. | · | tweet ↗ |
| 2026-10-14 | GILD | @BioStocks | +0.05 | Reports a VIR-GILD oncology collaboration with $90 million upfront and a premium equity investment. | +1.6% | tweet ↗ |
| 2026-10-14 | RARE | @BioStocks | +0.35 | Reports RARE sold a priority-review voucher for $203 million. | · | tweet ↗ |
| 2026-10-14 | ATRA | @BioStocks | +0.50 | FDA accepted ATRA's BLA resubmission and set a March 31, 2027 PDUFA date. | · | tweet ↗ |
| 2026-10-14 | VKTX | @BioStocks | +0.10 | Details enrollment and endpoints for two VK2735 clinical trials. | -4.2% | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.